Although the current well-established clinical and histological factors and some other well-defined biological factors (e.g., hormone receptors and HER2 status) have been established and are assessed routinely in therapy decision-making and evaluating the prognosis, there are increasing concerns that these prognostic determinants are limited in their ability to capture the diversity of clinical behaviors of breast cancer and that they would be insufficient to predict the response to specific treatment strategies for individual patients. Here, ERBB2 is linked to breast carcinoma.